- Home
- ECOR
ECOR
electroCore Inc.
as 12-17-2024 4:00pm EST
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | ROCKAWAY |
| Market Cap: | 65.0M | IPO Year: | 2018 |
| Target Price: | $15.00 | AVG Volume (30 days): | 97.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.25 - $15.25 | Next Earning Date: | 11-13-2024 |
| Revenue: | $23,327,000 | Revenue Growth: | 74.10% |
| Revenue Growth (this year): | 61.4% | Revenue Growth (next year): | 38.43% |
Latest electroCore Inc. News
ECOR Breaking Stock News: Dive into ECOR Ticker-Specific Updates for Smart Investing
MT Newswires
15 hours ago
electroCore to Acquire NeuroMetrix to Become Diversified Player in Non-Invasive Wellness Treatments
GlobeNewswire
16 hours ago
NeuroMetrix to be Acquired by electroCore
GlobeNewswire
16 hours ago
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
Simply Wall St.
5 days ago
Loss-Making electroCore, Inc. (NASDAQ:ECOR) Expected To Breakeven In The Medium-Term
GlobeNewswire
a month ago
electroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Award
GlobeNewswire
a month ago
electroCore Donates gammaCore Sapphire for Real World Evaluation of nVNS in Trauma Among Israelis
Simply Wall St.
a month ago
electroCore Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
a month ago
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
Compare ECOR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ECOR electroCore Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.